drugset / Trial / NCT03353506

Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection

NCT03353506 ↗

Phase 2 Completed 11 enrolled Dina Kao University of Alberta · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Fecal microbiota transplantation (FMT) for the treatment of recurrent Clostridium difficile infection (RCDI) has traditionally been offered as fecal slurry administered by enema, nasogastric tube or endoscopy. Frozen oral capsules have also shown efficacy. The potential advantage of lyophilized FMT is the relative ease of manufacturing and storage compared with fecal slurry. Sterile fecal filtrate has previously been shown to prevent Clostridium difficile infection (CDI) recurrence, suggesting that live bacteria may not be needed. This study will compare lyophilized sterile fecal filtrate (LSFF) with lyophilized FMT (LFMT) in the treatment of recurrent Clostridium difficile infection (RCDI).

Timeline

Start
2018-02-14
Primary completion
2019-06-05
Completion
2019-10-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lyophilized fecal microbiota transplant Other / unclassified 15 unknown Oral
Subject Lyophilized sterile fecal filtrate Other / unclassified 15 unknown Oral